MRK and VRNA Related Headlines
Go Back- Merck completes $10 billion acquisition of Verona Pharma
- Merck Completes Acquisition of Verona Pharma
- Verona Pharma shareholders approve $10 billion Merck acquisition
- Shareholders of Verona Pharma Approve Proposed Acquisition by Merck
- Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results
- Morgan Stanley Reiterates Equalweight Rating on Merck (MRK)
- Jefferies Downgrades Verona Pharma (VRNA) to Hold
- Stifel: 'MRK Acquisition of VRNA Should Broaden Opportunity for Ohtuvayre – A Core LGND Growth Driver'
- Merck to acquire Verona Pharma for $10 billion to add COPD treatment
- Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade
MRK and VRNA Related Press Releases
Go Back- Merck Completes Acquisition of Verona Pharma
- Shareholders of Verona Pharma Approve Proposed Acquisition by Merck
- Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results
- Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade
